BIG PHARMA EARNINGS WATCH: BRISTOL MYERS SQUIBB AND MERCK
Nov 11, 2024
Big Pharma Giants Conclude Latest Round of Earnings Reports Fueled by… Read More
© 2024 CSRXP- All Rights Reserved
Updates
BIG PHARMA EARNINGS WATCH: NOVARTIS AND PFIZER
Nov 8, 2024
Big Pharma Giants Keep Beating Wall Street Expectations While Continuing to… Read More
BIG PHARMA EARNINGS WATCH: ABBVIE, AMGEN AND GSK
Nov 7, 2024
Big Pharma Giants Rolling in Strong Earnings While Continuing to Hike Drug… Read More
BIG PHARMA EARNINGS WATCH: ROCHE AND SANOFI
Oct 28, 2024
Big Pharma Giants Continue Reporting Expectation-Beating Q3 Earnings After… Read More
SECOND OPINION: BIG PHARMA ONCE AGAIN TRIES TO DEFEND THE PATENT ABUSE STATUS QUO
Oct 23, 2024
Eli Lilly Opinion Column Reiterates Debunked Arguments on Innovation as Brand… Read More
BIG PHARMA EARNINGS: JOHNSON & JOHNSON
Oct 17, 2024
Johnson & Johnson Reports Higher-Than-Expected Earnings Fueled by Price… Read More
DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1 WEIGHT LOSS DRUG PRICES COULD COST MEDICARE $35 BILLION
Oct 10, 2024
CBO Confirms Cost of Blockbuster Obesity Drugs at Current Prices Would… Read More
DOSE OF REALITY: BRAND NAME DRUG MAKERS INCREASINGLY UTILIZING ‘USE CODES’ TO GAME PATENT SYSTEM AND BLOCK COMPETITION
Sep 30, 2024
STAT Analysis Finds Drug Makers Gaming FDA Orange Book Process to Further… Read More
CSRxP: SENATE JUDICIARY COMMITTEE SHOULD REJECT PHARMA-SUPPORTED POLICIES THAT WOULD UNDERMINE BIPARTISAN PROGRESS ON PATENT ABUSE
Sep 25, 2024
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
CSRxP ENCOURAGES HELP COMMITTEE TO ADVANCE BIPARTISAN SOLUTIONS TO PROMOTE GREATER COMPETITION IN THE PRESCRIPTION DRUG MARKET
Sep 24, 2024
Legislation Scheduled for Thursday Markup Would Encourage Adoption of… Read More
CSRxP: BIG PHARMA’S EGREGIOUS GLP-1 PRICES AND ANTI-COMPETITIVE TACTICS UNSUSTAINABLE FOR PATIENTS AND U.S. HEALTH CARE SYSTEM
Sep 24, 2024
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
DOSE OF REALITY: BIG PHARMA’S GLP-1 PRICE-GOUGING UNSUSTAINABLE FOR AMERICAN PATIENTS AND THE U.S. HEALTH SYSTEM
Sep 23, 2024
Brand Name Drug Companies Applying Price-Hiking, Patent Abuse Playbook to… Read More